C. Michael Gibson/cardiometabolichealth.org
Aug 29, 2026, 14:39
C. Michael Gibson: SINGLE-AF Trial Supports DOAC Use in Intermediate-Risk Atrial Fibrillation
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, Executive Board Member at EXCITE International, shared a post on LinkedIn:
“Single-AF trial: In patients with atrial fibrillation and intermediate stroke risk, DOAC therapy lowered the risk of net adverse clinical events (stroke, systemic embolism, major bleeding, or CV death) compared to no anticoagulation at 24 months.
Download slides here.”
Stay updated with Hemostasis Today.
-
Aug 29, 2026, 16:03Marco De Giovanni: The Platelet – Serotonin Link Behind Severe COVID-19
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:53Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community
-
Aug 29, 2026, 15:49Ujjawal Agarwal: Alkem’s Fight Against Anemia in Rural Bihar
-
Aug 29, 2026, 15:44Christopher Cannon: Anticoagulation Shows Benefits Even in Low Risk Atrial Fibrillation Patients
-
Aug 29, 2026, 15:43Aniela Popescu: Heart Failure Care Enters a New Era With the 2026 ESC Guidelines